Ubs Group Ag Tenaya Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 26,138 shares of TNYA stock, worth $43,389. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,138

Previous 16,845 55.17%

Holding current value

$43,389

Previous $52,000 3.85%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.93 - $3.99 $17,935 - $37,079	9,293 Added 55.17%	26,138 $50,000
Q2 2024 Aug 13, 2024	SELL	$2.72 - $4.99 $253,860 - $465,721	-93,331 Reduced 84.71%	16,845 $52,000
Q1 2024 May 13, 2024	BUY	$2.88 - $6.8 $187,666 - $443,101	65,162 Added 144.76%	110,176 $576,000
Q4 2023 Feb 09, 2024	BUY	$1.73 - $3.39 $33,786 - $66,206	19,530 Added 76.64%	45,014 $145,000
Q3 2023 Nov 09, 2023	SELL	$2.55 - $5.65 $2,134 - $4,729	-837 Reduced 3.18%	25,484 $64,000
Q2 2023 Aug 11, 2023	BUY	$2.64 - $7.64 $30,602 - $88,562	11,592 Added 78.7%	26,321 $154,000
Q1 2023 May 12, 2023	BUY	$1.92 - $3.59 $5,124 - $9,581	2,669 Added 22.13%	14,729 $41,000
Q4 2022 Feb 08, 2023	BUY	$1.68 - $3.19 $20,260 - $38,471	12,060 New	12,060 $24,000
Q2 2022 Aug 10, 2022	SELL	$5.01 - $14.12 $531 - $1,496	-106 Reduced 28.88%	261 $1,000
Q1 2022 May 16, 2022	SELL	$9.41 - $19.3 $27,505 - $56,413	-2,923 Reduced 88.84%	367 $4,000
Q4 2021 Feb 14, 2022	BUY	$18.41 - $29.58 $53,665 - $86,225	2,915 Added 777.33%	3,290 $62,000
Q3 2021 Nov 15, 2021	BUY	$15.35 - $26.66 $5,756 - $9,997	375 New	375 $8,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

56.3M

Call Options Held

900

Put Options Held

400

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $68.7M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account